Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

PHASE3TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions
Pulmonary HypertensionChronic Obstructive Pulmonary Disease
Interventions
DRUG

Inhaled treprostinil solution

Inhaled treprostinil solution per dose and schedule specified in the arm

Trial Locations (30)

10029

Mount Sinai Medical Center, New York

12208

Albany Medical Center, Albany

14623

University of Rochester Medical Center, Rochester

15212

Allegheny General Hospital, Pittsburgh

15213

University of Pittsburgh Medical Center, Pittsburgh

21201

University of Maryland Medical Center, Baltimore

22042

Inova Fairfax Hospital, Falls Church

23230

Pulmonary Associates of Richmond, Inc., Richmond

24014

Carilion Clinic, Roanoke

27599

University of North Carolina at Chapel Hill, Chapel Hill

29425

Medical University of South Carolina, Charleston

30106

Georgia Clinical Research, Austell

30342

Pulmonary & Critical Care of Atlanta, Atlanta

32204

St. Vincent's Lung, Sleep, and Criticial Care Specialists, Jacksonville

32224

Mayo Clinic - Jacksonville, Jacksonville

33136

University of Miami Hospital, Miami

33765

St. Francis Sleep Allergy & Lung Institute, Clearwater

34362

Lady Davis Carmel Medical Centre, Haifa

35294

The University of Alabama at Birmingham, Birmingham

40202

Kentuckiana Pulmonary Associates, Louisville

44195

Cleveland Clinic, Cleveland

45219

The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati

46260

St. Vincent Medical Group, Inc., Indianapolis

49100

Rabin Medical Center, Petah Tiva

49546

Spectrum Health, Grand Rapids

53792

University of Wisconsin School of Medicine and Public Health, Madison

60612

University of Illinois Medical Center, Chicago

95817

University of California Davis Medical Center, Sacramento

9112001

Hadassah-Hebrew University Hospital, Jerusalem

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Lung Biotechnology PBC

INDUSTRY

lead

United Therapeutics

INDUSTRY

NCT03794583 - Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) | Biotech Hunter | Biotech Hunter